Project Grant R41TR006357
Award Date 7/1/26
Completion Date 6/30/27
Dollars Obligated $323K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC, USA
Similar Awards
- Federal Grant Award Summary Capienda Biotech, LLC received a $329,272 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) awarded August 1, 2025, with completion expected January 31, 2027. The company is developing an innovative high-throughput kinetic screening instrument to accelerate small-molecule drug discovery targeting kinase enzymes. Building on a prior NSF Small Business Innovation Research Phase I prototype capable of 128 simultaneous tests,...
- Federal Grant Award Summary Cellchorus Inc. received a $399,625 Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) for the period of September 1, 2025, through August 31, 2027. The award supports the development of functional signatures for post-infusion Chimeric Antigen Receptor (CAR) T cells to enable early prediction of patient response to therapy in relapsed/refractory large B cell lymphoma (R/RLBCL) treatment. The project leverages...
- Federal Grant Award Summary Celdara Medical, LLC received a $310,564 Project Grant from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) for the period July 1, 2026 through June 30, 2027. The award funds development of engineered regulatory T cells (Tregs) as a therapeutic intervention for Gaucher disease, a lysosomal storage disorder characterized by deficiency of the enzyme glucocerebrosidase (GCase). The project delivers research and development services focused...
- Grant Award Summary Spectral Therapeutics, Inc. received a $322,388 Project Grant award from the National Center for Advancing Translational Sciences (NCATS, CFDA 93.350) effective August 1, 2025, through July 31, 2026, to develop and validate an optical-encoded bead technology platform for large-scale molecular library generation. The project addresses a critical bottleneck in combinatorial drug discovery by creating stimulated emission-encoded beads that enable instantaneous decoding during...
- Federal Grant Award Summary Cytoagents Inc. received a $1.31 million Project Grant from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) awarded on September 22, 2025, with completion targeted for August 31, 2027. The award supports the development of CTO1681, an orally available pharmaceutical compound designed to prevent and mitigate cytokine release syndrome (CRS) in multiple myeloma patients undergoing chimeric antigen receptor (CAR) T-cell therapy....
- Federal Grant Award Summary Award: Project Grant | Funding Agency: National Center for Advancing Translational Sciences (NCATS) | Program: NCATS (CFDA 93.350) | Awardee: Simplusdx, Inc. | Amount: $306,299 | Award Date: July 1, 2025 | Performance Period: July 1, 2025 – June 30, 2026 Simplusdx, Inc. will develop and validate a rapid point-of-care testing platform for therapeutic drug monitoring of tacrolimus, a critical immunosuppressive medication used in organ transplantation. The project adapts...
- Federal Grant Award Summary Seattle Children's Research Institute received a $470,759 Project Grant from the National Cancer Institute (Cancer Treatment Research program, CFDA 93.395) effective September 1, 2025 through August 31, 2027. The award supports development of an innovative CAR-T (Chimeric Antigen Receptor T-cell) immunotherapy platform designed to overcome T-cell exhaustion in solid tumor treatment, specifically targeting hepatocellular carcinoma patients. The research deliverables...
- Federal Project Grant Award Summary Round Table Research, Inc., in collaboration with researchers at UNC-Chapel Hill, received a $305,031 Phase I Small Business Technology Transfer (STTR) award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective September 1, 2025 through August 31, 2026. The project advances engineered extracellular vesicle (EV) therapy for glioblastoma (GBM), the most aggressive form of brain cancer. The award supports the...
- Federal Grant Award Summary Koi Biotherapeutics Inc. received a $1,340,987 Project Grant from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), awarded August 12, 2025, with a completion date of July 31, 2027. The award funds development of a CAR-Enhancer platform designed to enhance the activity and persistence of Chimeric Antigen Receptor (CAR) T-cell therapy, a treatment modality that has demonstrated success against blood-borne malignancies...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $716,521 to Sloan-Kettering Institute for Cancer Research on August 25, 2025, under the Cancer Treatment Research program (CFDA 93.395). The award supports the development and clinical evaluation of DLL3-targeted IL18-secreting chimeric antigen receptor (CAR) T cells for treating small cell lung cancer (SCLC). The research initiative addresses a critical clinical need, as SCLC currently demonstrates...